MR prednisone

DRUG2 trials

Sponsors

Merck KGaA, Darmstadt, Germany, Amgen

Conditions

Rheumatoid Arthritis

Phase 3

Prednisone Timed-Release Tablet (TRT) Study: Modified-Release (MR) Formulation of Prednisone Compared to Standard Immediate-Release (IR) Prednisone in Participants With Rheumatoid Arthritis

CompletedNCT00146640

Merck KGaA, Darmstadt, GermanyRheumatoid Arthritis

Start: 2004-08-31End: 2007-01-31Updated: 2018-07-03

Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis

CompletedNCT00650078

AmgenRheumatoid Arthritis

Start: 2008-03-31End: 2009-05-31Updated: 2024-12-18

Related Papers

Delayed-release prednisone improves fatigue and health-related quality of life: findings from the CAPRA-2 double-blind randomised study in rheumatoid arthritis

RMD Open2015-08-0121 citations

Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2).

2012-05-05121 citations

Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone.

2010-08-0351 citations

Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial.

2008-01-01225 citations